| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Medline Inc.$41.04
-0.76 (-1.85%)
C 45Pipeline Score MedTech · Commercial
Market Cap
48.62 B
EPS
1.20
P/E Ratio
30.96 $
Value Trade
527.50 M
SEC Financials
Q1 2026Dilution Risk
Revenue
7.35 B
Operating CF
412.00 M
Total Assets
39.01 B
Total Liabilities
19.66 B
Equity
11.27 B
D/E Ratio
12,345
-4.98 %
Week
-22.77 %
1 Month
-21.71 %
3 Month
-2.99 %
6 Month
-2.99 %
5 Year
-2.99 %
All Time
Cash Data
Cash Position
2.24 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
3.14 M
52 Week Range
35.50 - 50.88
% held by Insiders
36.15 %
% held by Institutions
62.19 %
Enterprise Value
67.10 B
Total Shares
786.57 M
Short %
16.02 %
Float Shares
226.53 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Medline Inc.
17Total events
2Upcoming
2Tier-1 (high impact)
2025 – 2027Coverage
Upcoming catalysts 2
Event history 15
Q3 2026
▲Product LaunchPost-Market
Medline Canada begins warehouse and supply chain logistics for Mohawk Medbuy hospitals
Jun 23, 2026
▲Partnership / LicenseCorporate
Access Vascular and Medline enter multi-year agreement to launch cobranded next-generation vascular access catheters
vascular accesssource ↗
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference presentation
Jun 3, 2026
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference presentation
May 29, 2026
▲Partnership / LicenseCorporate
Medline Canada signs first Prime Vendor agreement with Mohawk Medbuy
May 28, 2026
▼Equity OfferingCorporate
Upsized secondary offering of 72,554,594 shares of Class A common stock closed at $37.00 per share
May 21, 2026
▼Equity OfferingCorporate
Pricing of upsized secondary offering of Class A common stock at $37.00 per share
Mar 11, 2026
◆Oral PresentationPresentation
Medline presents at Barclays 28th Annual Global Healthcare Conference
Mar 4, 2026
▼Equity OfferingCorporate
Pricing of secondary offering of 75,000,000 shares at $41.00 per share
Mar 3, 2026
▼Equity OfferingCorporate
Selling stockholders commence underwritten public offering of 75,000,000 shares of Class A common stock
Feb 25, 2026
Drug Pipeline Intelligence
C45
Pipeline Score $1.7B
Pipeline ValueValuation Signal
5
Drugs Scored0.1x
rNPV / MCap Top 66%
Mid Cap (rank 311 of 911)
Percentile RankMedline Inc. carries a moderate pipeline score (45/100), with $2.0B risk-adjusted pipeline value, led by Chlorhexidine Gluconate in Surgery (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chlorhexidine Gluconate Small molecule | Surgery | Phase 3 | NCT02291601 | 50% | $647M | COMPLETED | 1,566 | - | - | Sep 1, 2015 | - | Apr 30, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDLN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MDLN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDLN▼ -1.8%today
Medline announces Prime Vendor agreement with Allina Health
Medline has entered into a Prime Vendor agreement with Allina Health, enhancing access to its medical-surgical products and supply chain solutions. This partnership aims to improve supply reliability and streamline the ordering process for Allina Health's network of hospitals and clinics. Both organizations emphasize the importance of supporting quality patient care through this collaboration.
Read more →MDLNSecuring new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
Medline has secured two new distribution centers in Northern California, totaling over 1.6 million square feet, to replace a facility lost to fire. This expansion represents a 45% increase in their customer-facing footprint in the region. The new centers will enhance service capabilities for healthcare providers and are expected to incorporate advanced technologies.
Read more →MDLN▲ +5.8%on this newsshared move
Medline to report second quarter 2026 results on August 5, 2026
Medline Inc. has announced its plan to report second quarter 2026 financial results on August 5, 2026. A press release and supplemental materials will precede the market opening. The company will also host a conference call and webcast to discuss the results, with details available on its Investor Relations website.
Read more →MDLNAccess Vascular and Medline Enter Multi-Year Agreement to Launch Cobranded Next-Generation Vascular Access Catheters
Access Vascular and Medline have announced a multi-year agreement to launch cobranded next-generation vascular access catheters. This partnership aims to enhance the quality and efficiency of vascular access solutions. The details regarding the specific features and benefits of the new catheters have not been disclosed.
Read more →MDLNMedline Expands Manufacturing Footprint in Slovakia to Support Long-Term Growth in Europe
Medline International B.V. is expanding its manufacturing facility in Partizánske, Slovakia, to enhance production capacity and support growth in Europe. The new facility, set to begin operations in 2027, will feature advanced clean room technology and energy-efficient systems. This expansion underscores Medline's commitment to operational excellence and sustainability while creating new job opportunities.
Read more →MDLNMedline étend sa présence industrielle en Slovaquie pour soutenir sa croissance à long terme en Europe
Medline International B.V. is expanding its manufacturing facility in Partizánske, Slovakia, to enhance production capacity and support long-term growth in Europe. The new facility, set to begin operations in 2027, will improve operational efficiency and reliability for clients. This strategic investment underscores Medline's commitment to quality and sustainability in healthcare solutions.
Read more →MDLNMedline erweitert seine Produktionskapazitäten in der Slowakei, um das langfristige Wachstum in Europa zu unterstützen
Medline International B.V. is expanding its production facility in Partizánske, Slovakia, to enhance its manufacturing capacity and support long-term growth in Europe. The new facility is set to begin operations in 2027 and will include advanced cleanroom technology. This expansion aims to improve efficiency and reliability for customers while creating new jobs in the region.
Read more →MDLNMedline amplía su presencia manufacturera en Eslovaquia para respaldar el crecimiento a largo plazo en Europa
Medline International B.V. is expanding its manufacturing presence in Partizánske, Slovakia, to enhance production capacity and support long-term growth in Europe. The new facility, set to begin operations in 2027, will feature improved operational flows and a cleanroom. This expansion reflects Medline's commitment to excellence and sustainability in healthcare solutions.
Read more →MDLNMedline’s Prime Vendor model expands outside the United States
Medline has signed its first Prime Vendor agreement in Canada with Mohawk Medbuy, marking a significant expansion of its services outside the U.S. This agreement aims to improve supply chain logistics for hospitals in Southwestern Ontario by implementing a stockless distribution model. The initiative is expected to enhance service reliability and efficiency in healthcare delivery.
Read more →MDLNMedline's Prime Vendor model expands outside the United States
Medline has signed its first Prime Vendor agreement in Canada with Mohawk Medbuy, marking a significant expansion outside the U.S. This partnership aims to enhance supply chain logistics for hospitals in Southwestern Ontario by implementing a stockless distribution model. The agreement is expected to improve service reliability and efficiency in delivering medical supplies.
Read more →MDLNMedline Inc. announces closing of upsized secondary offering of Class A common stock
Medline Inc. has successfully closed its upsized secondary offering of 72,554,594 shares of Class A common stock at $37.00 per share. The offering was conducted by selling stockholders affiliated with Blackstone Inc. and others, while Medline did not sell any shares or receive proceeds. The underwriters have a 30-day option to purchase additional shares.
Read more →MDLNMedline announces participation in upcoming investor conferences
Medline Inc. has announced its participation in two upcoming investor conferences. The company's CFO and CPO will present at the William Blair Annual Growth Stock Conference, while the CEO and CFO will present at the Goldman Sachs Global Healthcare Conference. Webcasts of these presentations will be available for investors.
Read more →MDLNMedline Inc. announces pricing of upsized secondary offering of Class A common stock
Medline Inc. has announced the pricing of its upsized secondary offering of 72,554,594 shares of Class A common stock at $37.00 per share. The offering, which is set to close on May 28, 2026, involves selling stockholders affiliated with Blackstone Inc. and others. Medline will not receive any proceeds from the sale, as it is not selling any shares.
Read more →MDLNMedline expands animal health portfolio with spay/neuter surgical packs
Medline has launched custom spay/neuter surgical packs aimed at improving efficiency in veterinary practices and animal shelters. These ready-to-use packs consolidate essential surgical instruments, allowing for quicker patient turnover. The Pensacola Humane Society has successfully implemented these packs, enhancing their surgical capabilities and supporting their mission to help more animals find permanent homes.
Read more →MDLNMedline deploys new AutoStore installation at distribution center in Aurora, Colorado
Medline has launched a new AutoStore installation at its Aurora, Colorado distribution center to enhance efficiency and order capacity. This installation, featuring 96 robots and 38,000 bins, is part of Medline's strategy to modernize its supply chain and meet increasing customer demand. The initiative is supported by Swisslog's SynQ software to streamline operations.
Read more →MDLN▼ -7.3%on this news
Document
Medline Inc. reported its first quarter 2026 financial results, revealing a net sales increase of 10.7% to $7.4 billion despite a 25.8% decline in net income. The company raised its full year guidance for organic sales to between 8.5% and 9.5%, reflecting strong customer growth and implementation efforts. However, higher costs of goods sold and operating expenses negatively impacted net income and adjusted EBITDA for the quarter. The results highlight both growth potential and financial challenges facing Medline.
Read more →MDLN▼ -7.3%on this news
Medline Reports First Quarter 2026 Results
Medline reported its first quarter 2026 results, showing a 10.7% increase in net sales to $7.4 billion, driven by customer growth. However, net income fell by 25.8% to $239 million, attributed to higher costs and expenses. The company raised its full-year Organic Sales guidance to 8.5%-9.5% while maintaining its Adjusted EBITDA outlook.
Read more →MDLNMedline officially launches Mpower™, a digital control tower designed to predict, respond and resolve supply chain risks
Medline has launched Mpower™, a cloud-based AI-powered supply chain technology aimed at enhancing healthcare providers' ability to predict and respond to supply chain disruptions. Developed in collaboration with Microsoft, Mpower offers real-time insights and automates workflows, significantly improving operational efficiency. Initial users report a more than 50% gain in order substitution efficiency, indicating its potential impact on healthcare supply chains.
Read more →MDLNMedline announces first-in-healthcare AI robotics partnership with Symbotic
Medline has entered a strategic partnership with Symbotic to implement AI-enabled robotics in its supply chain. This initiative marks Medline as the first healthcare company to adopt such technology, which aims to improve distribution efficiency and scalability. The pilot program is set to launch in 2027 at one of Medline's distribution centers.
Read more →MDLNMedline to report first quarter 2026 results on May 6, 2026
Medline Inc. has announced that it will report its first quarter 2026 financial results on May 6, 2026. The company will provide a press release and supplemental materials before the market opens. A conference call and webcast will follow at 9:30 AM ET to discuss the results, with a replay available afterward.
Read more →MDLNMedline launches custom product fulfillment technology called Pick Pack Pro™
Medline has introduced a new fulfillment system called Pick Pack Pro™ at its Montgomery, N.Y. distribution center. This advanced automation technology aims to enhance the delivery of medical supplies directly to health plan members' homes. The system integrates robotic sortation and automated packing to improve order accuracy and speed, addressing the unique needs of health plan orders. Medline plans to expand this technology across its distribution network to further support health plan providers.
Read more →MDLNMedline recognizes manufacturing facilities with Golden Cone Safety Award
Medline has awarded its Golden Cone Safety Awards to its top manufacturing facilities in the U.S., recognizing their commitment to safety and employee engagement. The awards are based on safety metrics and the execution of annual safety plans. Facilities in North Mankato, Arlington Heights, and Laredo were highlighted for their exemplary safety practices.
Read more →MDLNMedline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
Medline has received two prestigious awards from the Healthcare Industry Resiliency Collaborative (HIRC) for its exemplary supply chain partnerships and resiliency. The company was recognized for its long-term collaborative approach with healthcare providers and its operational rigor. Additionally, Medline renewed its Transparency Badge, reinforcing its commitment to supply chain visibility and customer collaboration.
Read more →MDLNMedline Inc. announces pricing of secondary offering of class A common stock
Medline Inc. has announced the pricing of a secondary offering of 75 million shares of its Class A common stock at $41.00 per share. The offering, which is set to close on March 10, 2026, involves selling stockholders affiliated with major investment firms. Medline will not sell any shares or receive proceeds from the offering.
Read more →MDLNMedline Inc. announces launch of secondary offering of Class A common stock
Medline Inc. has announced a secondary offering of 75 million shares of its Class A common stock, led by selling stockholders affiliated with major investment firms. The company will not sell any shares or receive proceeds from the offering. The underwriters have a 30-day option to purchase additional shares. This move reflects Medline's ongoing capital strategy.
Read more →MDLNMedline Reports Fourth Quarter and Full Year 2025 Results
Medline Inc. reported strong financial results for Q4 and the full year 2025, with net sales reaching $7.8 billion in Q4, up 14.8% from the previous year. Despite a decrease in net income due to higher costs, the company successfully completed its IPO and anticipates continued growth in 2026, projecting organic sales growth of 8% to 9%. The results reflect strong customer confidence in Medline's services and capabilities.
Read more →MDLNDocument Medline Reports Fourth Quarter and Full Year 2025 Results Delivered strong full year 2025 results Completed Initial Public Offering Introduced full year 2026 guidance Fourth quarter net sales of $7.8 billion, an
Medline Inc. has reported strong results for the fourth quarter and full year 2025, with net sales reaching $28.4 billion and a notable increase in customer signings. Despite these achievements, the company faced challenges including a 37.7% decrease in fourth quarter net income and rising costs associated with tariffs and headcount investments. The completion of its Initial Public Offering marks a crucial milestone for Medline, which is optimistic about continued growth, projecting an Organic Sales increase of 8% to 9% for the upcoming year. Overall, while the company's sales figures are strong, higher operational costs have affected profitability.
Read more →MDLNMedline announces participation in the Barclays 28th Annual Global Healthcare Conference
Medline Inc. has announced its participation in the Barclays 28th Annual Global Healthcare Conference, scheduled for March 11, 2026. CEO Jim Boyle and CFO Mike Drazin will present at the event in Miami Beach, FL. A webcast of the presentation will be accessible on Medline's Investor Relations website, with a replay available for six months.
Read more →MDLNMedline to report fourth quarter and full year 2025 results on February 25, 2026
Medline Inc. has announced that it will report its fourth quarter and full year 2025 financial results on February 25, 2026. A press release and supplemental materials will be available before the market opens, followed by a webcast and conference call to discuss the results. Medline is recognized as the largest provider of medical-surgical products globally.
Read more →Competitive Position
How MDLN ranks across every disease it competes inCompetitive Position is a premium feature
See how MDLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial